Therapeutic Drug Monitoring

Papers
(The H4-Index of Therapeutic Drug Monitoring is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Prospective Validation of a Nomogram for Determining the Optimal Dose of Lamotrigine for Augmentation Therapy in Patients With Treatment-Resistant Depression65
Designer Benzodiazepines: Effects, Toxicity, and Interactions60
Relationship Between Amphetamine Concentrations in Saliva and Serum in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder54
Association of Vancomycin Trough Concentration and Clearance With Febrile Neutropenia in Pediatric Patients49
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data46
Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study45
Gentamicin Assay Considering Both Analytical and Clinical Guidelines: A Square Peg in a Round Hole—Letter to the Editor37
PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography—Tandem Mass Spectrometry33
Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?29
Ceftazidime Plasma Concentrations and Neurotoxicity: The Importance of Therapeutic Drug Monitoring in Patients Undergoing Different Modalities of Renal Replacement Therapy. A Grand Round24
A Broad Range High-Throughput Assay for Lenvatinib Using Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry With Clinical Application in Patients With Hepatocellular Carc24
Optimization of Teicoplanin Dosing Regimen in Adult Patients Using an Externally Evaluated Population Pharmacokinetic Model23
In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine23
Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program21
Simultaneous Determination of Rifamycin Antibiotics and Their Active Metabolites in Human Plasma Using UHPLC-MS/MS to Evaluate Their Impact on Target Peak Concentrations: A Short Communication19
Drug–Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir–Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fi19
Therapeutic Drug Monitoring Consulting Cannot be Ruled out by Model-Informed Precision Dosing17
0.053168058395386